延伸曲线与灵活的超参数选择相匹配,以预测长效PEGylated生长激素治疗对生长激素缺乏症儿童的反应:方法开发和验证
Ling Hou1, Junfen Fu2, Haiyan Wei3
1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Journal of endocrinological investigation
|February 19, 2025
概括
这项研究使用曲线匹配改进了生长激素缺乏症 (GHD) 的儿童的身高轨迹预测. 改进的方法准确预测长效生长激素治疗的反应.
科学领域:
- 儿科 儿科 儿科
- 内分泌学 在内分泌学.
- 生物统计学 生物统计学
背景情况:
- 纵向生长数据分析对于预测儿童身高轨迹至关重要.
- 生长激素缺乏症 (GHD) 需要有效的治疗监测.
- 长效生长激素疗法可以改善患者的服从性和结果.
研究的目的:
- 加强曲线匹配方法,以预测患有GHD的儿童的身高轨迹.
- 为了提高长效生长激素治疗对治疗反应的预测准确度.
主要方法:
- 使用了681名儿童的现实数据集,这些儿童接受了36个月的PEGylated复合人体生长激素 (PEG-rhGH) 治疗.
- 在匹配的数据库中使用破碎棒方法来赋值高度测量.
- 开发了一种灵活的超参数选择方法,用于确定相同患者的最佳数量,以实现曲线匹配.
主要成果:
- 灵活的超参数方法显著提高了与固定患者数量 (p <0.05) 相比的预测准确性.
- 在治疗的前六个月内,通过四次高度测量实现了最佳预测.
- 平均二次误差证明了拟议方法的卓越性能.
结论:
- 扩展曲线与灵活的超参数选择相匹配,可准确预测GHD儿童的治疗反应.
- 这种方法有助于优化长效PEG-rhGH疗法,用于儿科GHD患者.
- 准确的预测有助于个性化治疗策略和监测.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...


